Skip to main content

Rixubis FDA Approval History

FDA Approved: Yes (First approved June 26, 2013)
Brand name: Rixubis
Generic name: coagulation factor IX (recombinant)
Dosage form: Injection
Company: Baxter International Inc.
Treatment for: Hemophilia B

Rixubis (coagulation factor IX, recombinant) is an antihemophilic factor indicated for the control and prevention of bleeding episodes in adults with hemophilia B.

Development timeline for Rixubis

Jun 27, 2013Approval FDA Approves Rixubis - First Recombinant Coagulation Factor IX For Use in Preventing Bleeding Episodes

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.